To include your compound in the COVID-19 Resource Center, submit it here.

Product Development
NIH, Warp Speed streamline preventive mAb, vaccine testing via clinical trial network

On the back of its first COVID-19 mAb investment, Operation Warp Speed launched a clinical trial network with NIH on Wednesday to streamline testing of the modality in prophylactic ...

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe ...

Chromatin remodeling gains traction with Merck-Foghorn partnership

Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction.

Under the deal, Merck & Co. Inc. (NYSE:MRK) will ...

VelosBio jumps on megaround bandwagon with $137M series B

With its $137 million series B round Wednesday, VelosBio became the 50th biotech this year to raise a venture round topping the $100 million mark (see

Data Bytes: preclinical IPOs raising big bucks in 2020

In the first half of 2020,

Read the full 60 word article

Ascendis leads latest pack of follow-ons with $600M raise

Four therapeutics companies raised nearly $1.2 billion in follow-ons after market close Tuesday, signaling sustained investor demand for biotech

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

CapitalBio Technology raises over $113M in pre-IPO round
CapitalBio Corp. subsidiary CapitalBio Technology Co Ltd. raised over RMB800 million ($113 million) in ...

Management Tracks
Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO ...

BioCentury ISSN 1097-7201